Search for Clinical Trial Results
Prostatic Neoplasms, Castration-Resistant - 21 Studies Found
Status | Study |
Not yet recruiting |
Study Name: Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) Condition: Prostatic Cancer, Castration-Resistant Date: 2016-08-08 Interventions: Drug: SXL01 |
Recruiting |
Study Name: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer Condition: Prostate Cancer Date: 2015-04-15 Interventions:
|
Recruiting |
Study Name: Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer Condition: Metastatic Castration-Resistant Prostatic Cancer Date: 2014-09-30 Interventions:
|
Terminated |
Study Name: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Condition: Castration-resistant Prostate Cancer Date: 2013-08-01 Interventions: Device: F-Choline-PET |
Completed |
Study Name: Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer Condition:
Date: 2007-10-09 Interventions:
|
Not yet recruiting |
Study Name: Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Condition:
|
Not yet recruiting |
Study Name: Combination Study of Guadecitabine and Pembrolizumab. Condition:
Date: 2016-11-02 Interventions:
|
Recruiting |
Study Name: Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases Condition: Castration-Resistant Prostatic Cancer Date: 2015-03-20 Interventions: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223) Dosage and treatment duration according to the decisio |
RECRUITING |
Study Name: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy Condition: Date: 2024-05-11 Interventions: To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer |
NOT_YET_RECRUITING |
Study Name: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2024-05-11 Interventions: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol |